Page last updated: 2024-11-10

sdz psc 833

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

valspodar: nonimmunosuppressive cyclosporin analog which is a potent multidrug resistance modifier; 7-10 fold more potent than cyclosporin A; a potent P glycoprotein inhibitor; MW 1215 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5281884
CHEMBL ID1086218
CHEBI ID8985
SCHEMBL ID17879
SCHEMBL ID21751941
MeSH IDM0191431

Synonyms (54)

Synonym
(3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-6,9,18,24-tetraisobutyl-3,21,30-triisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-[(e,2r)-2-methylhex-4-enoyl]-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
sdz-psc 833
cyclosporin d, 6-[(2s,4r,6e)-4-methyl-2-(methylamino)-3-oxo-6-octenoic acid]-
psc-833 ,
amdray
sdz-psc-833
psc 833
psc833
amdray (tn)
valspodar (usan/inn)
D06277
valspodar
121584-18-7
3'-keto-bmt(1)-val(2)-cyclosporin a
sdz psc 833
chebi:8985 ,
CHEMBL1086218
bdbm50390978
cyclosporin a, 6-((r-(e))-6,7-didehydro-n,4-dimethyl-3-oxo-l-2-aminooctanoic acid)-7-l-valine-
valspodar [usan:inn:ban]
cyclo(((2s,4r,6e)-4-methyl-2-(methylamino)-3-oxo-6-octenoyl)-l-valyl-n-methylglycyl-n-methyl-l-leucyl-l-valyl-n-methyl-l-leucyl-l-alanyl-d-alanyl-n-methyl-l-leucyl-n-methyl-l-leucyl-n-methyl-l-valyl)
cyclosporin d, 6-((2s,4r,6e)-4-methyl-2-methylamino)-3-oxo-6-octenoic acid)-
unii-q7zp55kf3x
q7zp55kf3x ,
HY-17384
CS-1074
6-[(2s,4r,6e)-4-methyl-2-(methylamino)-3-oxo-6-octenoic acid]-7-l-valine-cyclosporin a
SCHEMBL17879
Q-100733
AKOS024457945
valspodar [inn]
valspodar [mi]
valspodar [mart.]
valspodar [vandf]
valspodar [usan]
valspodar [who-dd]
J-004540
J-525155
sr-01000872585
SR-01000872585-1
valspodar(psc833)
DB11869
(3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-6,9,18,24-tetraisobutyl-3,21,30-triisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-((r,e)-2-methylhex-4-enoyl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone
SCHEMBL21751941
DTXSID90873386
EX-A2242
valspodar; (psc-833
AS-35155
mfcd00907207
Q7120613
sdz psc833
gtpl11745
cyclosporin a, 6-[(2s,4r,6e)-4-methyl-2-(methylamino)-3-oxo-6-octenoic acid]-7-l-valine-
6-[(2s,4r,6e)-4-methyl-2-(methylamino)-3-oxo-6-octenoicacid]-7-l-valinecyclosporin a

Research Excerpts

Overview

SDZ PSC 833 (PSC 833) is a cyclosporin A analogue that is under clinical investigation in combination with doxorubicin (Dx) or other anticancer agents as a type-1 multidrug resistance (MDR-1)-reversing agent.

ExcerptReferenceRelevance
"SDZ PSC 833 (PSC 833) is a cyclosporin A analogue that is under clinical investigation in combination with doxorubicin (Dx) or other anticancer agents as a type-1 multidrug resistance (MDR-1)-reversing agent. "( Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833.
Colombo, T; D'Incalci, M; De Fusco, M; Gonzalez, O; Imperatori, L; Zucchetti, M, 1995
)
1.95
"SDZ PSC 833 (PSC 833) is a non-immunosuppressive analogue of cyclosporin A and is a potent modifier of P-glycoprotein (P-gp)-mediated multidrug resistance. "( Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia.
Colombo, T; D'Incalci, M; Gonzalez Paz, O, 1996
)
1.98
"SDZ PSC 833 is an efficient MDR reversing agent as determined under monolayer conditions and is currently being evaluated in clinical trials."( The reversal of multidrug resistance in multicellular tumor spheroids by SDZ PSC 833.
Archinal-Mattheis, AE; Bair, KW; Cohen, D; Ehrlich, PH; Moustafa, ZA; Newman, MJ,
)
1.08
"SDZ PSC 833 is a novel compound able to reverse the resistance to chemotherapy of cancer cells with the multidrug resistance (MDR) phenotype by inhibiting the 170 kd P-glyco-protein (P-gp). "( [SDZ PSC 833: a novel modulator of MDR].
Covelli, A,
)
2.48
"SDZ PSC 833 (PSC 833) is a new multidrug resistance modulator. "( SDZ PSC 833 the drug resistance modulator activates cellular ceramide formation by a pathway independent of P-glycoprotein.
Cabot, MC; Giuliano, AE; Goulding, CW, 2000
)
3.19

Treatment

The treatment with SDZ PSC 833 did not affect calbindin-D28k or VDR expression, but did cause a 73% decrease in 24-OHase mRNA levels.

ExcerptReferenceRelevance
"The SDZ PSC 833 treatment resulted in important modifications of colchicine blood pharmacokinetics: the unbound colchicine blood concentration at steady-state was enhanced from 149.6 +/- 9.9 to 333.5 +/- 81.7 ng/ml indicating a two-fold decrease in colchicine clearance."( Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine.
Desrayaud, S; Guntz, P; Lemaire, M; Scherrmann, JM, 1997
)
1.05
"The treatment with SDZ PSC 833 did not affect calbindin-D28k or VDR expression, but did cause a 73% decrease in 24-OHase mRNA levels."( Evidence for the impairment of the vitamin D activation pathway by cyclosporine A.
Bobadilla, M; Chibout, SD; Grenet, O; Steiner, S, 2000
)
0.63

Toxicity

ExcerptReferenceRelevance
" Pgp may also be present in normal tissue, providing protection against toxic substances, but the physiological role of Pgp is not fully understood."( Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein.
Lehne, G; Rugstad, HE, 1998
)
0.3
" None of the Pgp blockers was toxic up to 10 microM, but amiodarone markedly increased CK leakage at 25 microM."( Effect of PSC 833, verapamil and amiodarone on adriamycin toxicity in cultured rat cardiomyocytes.
Estevez, MD; Schramm, U; Wolf, A, 2000
)
0.31
"To investigate the effect of acute P-glycoprotein inhibition by the multidrug-resistance (MDR) modulator valspodar (SDZ PSC 833; PSC) on the pharmacokinetics, and potentially adverse pharmacodynamic effects of morphine, and its principal pharmacologically active metabolites, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G)."( Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine.
Ball, HA; Beglinger, C; Drewe, J; Haefeli, WE; Kemmler, A; Peng, B; Schächinger, H, 2000
)
0.52
"In a double-blind, three-way crossover study, the pharmacokinetic and potentially adverse pharmacodynamic effects (reaction time, transcutaneous PCO2, blood pressure) of morphine were compared with and without acute inhibition of P-glycoprotein by PSC."( Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine.
Ball, HA; Beglinger, C; Drewe, J; Haefeli, WE; Kemmler, A; Peng, B; Schächinger, H, 2000
)
0.31
" PSC did not significantly affect the adverse events of morphine, as assessed by spontaneous reporting."( Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine.
Ball, HA; Beglinger, C; Drewe, J; Haefeli, WE; Kemmler, A; Peng, B; Schächinger, H, 2000
)
0.31
"Cyclosporine nephrotoxicity remains a major side effect in solid organ transplantation, and can be exacerbated by concomitant administration of sirolimus."( Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction.
Anglicheau, D; Beaune, P; Cassinat, B; Legendre, C; Marquet, P; Méria, P; Pallet, N; Rabant, M; Thervet, E, 2006
)
0.33
"Paraquat is a herbicide that is highly toxic to the lungs and kidneys following acute exposures."( MDR1 transporter protects against paraquat-induced toxicity in human and mouse proximal tubule cells.
Aleksunes, LM; Buckley, B; Gibson, CJ; Goedken, MJ; Richardson, JR; Wen, X; Yang, I, 2014
)
0.4
"Paclitaxel-induced peripheral neuropathy (PIPN) is a common and dose-limiting adverse event."( P-Glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Patients With Cancer.
Hammer, HS; Khalaf, S; Kroetz, DL; Mortensen, C; Nielsen, F; Poetz, O; Rodriguez-Antona, C; Stage, TB; Steffensen, V; Svenningsen, ÅF; Xiong, C, 2020
)
0.56

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic behavior of PSC 833 appears to be similar to that of cyclosporine."( Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist.
Bates, S; Figg, WD; Fojo, AT; Kalafsky, G; Lush, RM; Meadows, B; Smith, HT, 1997
)
0.3
" The use of microdialysis for pharmacokinetic studies was validated by comparing the blood concentrations of colchicine obtained by microdialysis with those obtained by direct blood sampling."( Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine.
Desrayaud, S; Guntz, P; Lemaire, M; Scherrmann, JM, 1997
)
0.56
" Serial determinations of total bilirubin were explored as a potential pharmacodynamic marker for P-glycoprotein inhibition."( Optimizing the absorption of valspodar, a P-glycoprotein modulator, Part I: Selecting an oral formulation and exploring its clinical pharmacokinetics/dynamics.
Hensel, S; Holt, B; Kovarik, JM; Lücker, PW; Mueller, EA; Preisig-Flückiger, SS; Uresin, Y, 1997
)
0.3
"A randomized, sequential, bioreplication study was performed with 24 healthy volunteers to assess the pharmacokinetic variability of oral and intravenous administrations of valspodar, a multidrug resistance modulator for use as a chemotherapy adjunct."( Optimizing the absorption of valspodar, a P-glycoprotein modulator, Part II: Quantifying its pharmacokinetic variability and refining the bioavailability estimate.
Kovarik, JM; Mueller, EA; Richard, F; Tetzloff, W, 1997
)
0.3
" Pharmacokinetic analyses of PSC and doxorubicin were performed."( A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors.
Catimel, G; Eeltink, C; Giaccone, G; Linn, SC; Pinedo, HM; Stieltjes, H; van der Vijgh, WJ; Vermorken, JB; Welink, J, 1997
)
0.52
"Lack of a pharmacokinetic drug-drug interaction with respect to valspodar was conclusively demonstrated for both Cmax,b (2."( Pharmacokinetics of dexamethasone and valspodar, a P-glycoprotein (mdr1) modulator: implications for coadministration.
Gerbeau, C; Humbert, H; Kovarik, JM; Mueller, EA; Pongowski, M; Purba, HS,
)
0.13
" In the present investigation, we characterized the excretory processes associated with liposomal DOX administration to elucidate how liposome encapsulation may bypass adverse pharmacokinetic interactions between DOX and (3'-keto-Bmt1)-(Val2)-cyclosporin (Valspodar)."( Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion.
Krishna, R; Mayer, LD; McIntosh, N; Riggs, KW, 1999
)
0.3
"To investigate the effect of acute P-glycoprotein inhibition by the multidrug-resistance (MDR) modulator valspodar (SDZ PSC 833; PSC) on the pharmacokinetics, and potentially adverse pharmacodynamic effects of morphine, and its principal pharmacologically active metabolites, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G)."( Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine.
Ball, HA; Beglinger, C; Drewe, J; Haefeli, WE; Kemmler, A; Peng, B; Schächinger, H, 2000
)
0.52
"In a double-blind, three-way crossover study, the pharmacokinetic and potentially adverse pharmacodynamic effects (reaction time, transcutaneous PCO2, blood pressure) of morphine were compared with and without acute inhibition of P-glycoprotein by PSC."( Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine.
Ball, HA; Beglinger, C; Drewe, J; Haefeli, WE; Kemmler, A; Peng, B; Schächinger, H, 2000
)
0.31
" were unaffected there was a small but statistically significant increase in the AUC and Cmax of M3G (11."( Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine.
Ball, HA; Beglinger, C; Drewe, J; Haefeli, WE; Kemmler, A; Peng, B; Schächinger, H, 2000
)
0.31
"Acute inhibition of P-glycoprotein by PSC in this setting does not affect the pharmacokinetic or safety-related pharmacodynamic profile of morphine in a clinically significant manner."( Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine.
Ball, HA; Beglinger, C; Drewe, J; Haefeli, WE; Kemmler, A; Peng, B; Schächinger, H, 2000
)
0.31
"In recent years, there has been an increased understanding of P-glycoprotein (P-GP)-mediated pharmacokinetic interactions."( Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs.
Krishna, R; Mayer, LD, 2000
)
0.31
"To evaluate the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetic (PK) profile of paclitaxel and carboplatin when administered every 3 weeks with the oral semisynthetic cyclosporine analog valspodar (PSC 833), an inhibitor of P-glycoprotein function."( Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.
Egorin, MJ; Fracasso, PM; Kerr, I; Litchman, M; Michael, M; Moore, MJ; Oza, AM; Patnaik, A; Rivkin, S; Siu, LL; Warner, E, 2000
)
0.31
" The pharmacokinetic model generated from this study allows for application in future studies to optimize the use of valspodar."( Pharmacokinetic study of infusional valspodar.
Fracasso, PM; Ma, MK; McLeod, HL; Westervelt, P, 2002
)
0.31
"025), which contributed to a minor difference in the terminal disposition half-life (6."( Effect of valspodar on the pharmacokinetics of unbound paclitaxel.
Doroshow, JH; Sparreboom, A; Spicer, D; Synold, TW; ten Tije, AJ; Verweij, J, 2003
)
0.32
" No effect of valspodar on other pharmacokinetic parameters was discernible."( Modeling methadone pharmacokinetics in rats in presence of P-glycoprotein inhibitor valspodar.
Calvo, R; Ortega, I; Perez-Ruixo, JJ; Rodriguez, M; Suarez, E, 2007
)
0.34
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Plasma pharmacokinetic parameters of valspodar in its polymeric micellar formulation were compared to its clinical formulation, which uses Cremophor EL and ethanol as solubilizing agents."( Development of a polymeric micellar formulation for valspodar and assessment of its pharmacokinetics in rat.
Binkhathlan, Z; Brocks, DR; Hamdy, DA; Lavasanifar, A, 2010
)
0.36
"To develop a novel intestinal drug absorption system using intestinal epithelial cells derived from human induced pluripotent stem (iPS) cells, the cells must possess sufficient pharmacokinetic functions."( Pharmacokinetic functions of human induced pluripotent stem cell-derived small intestinal epithelial cells.
Imakura, Y; Iwao, T; Kabeya, T; Matsunaga, T; Mima, S; Miyashita, T; Ogura, I; Yamada, T; Yasujima, T; Yuasa, H, 2020
)
0.56

Compound-Compound Interactions

ExcerptReferenceRelevance
" We performed a dose escalation study of SDZ PSC 833 combined with VAD chemotherapy in refractory multiple myeloma (MM)."( Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
Charnick, S; Faussat, AM; Groenewegen, A; Huisman, C; Löwenberg, B; Marie, JP; Schoester, M; Sonneveld, P; van Kapel, J; Vekhoff, A; Zittoun, R, 1996
)
0.83
" Modest modulation of P-glycoprotein-mediated MDR was observed in the murine P388/ADR solid tumor model when PSC 833 was administered with free DOX at the MTD."( Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
Krishna, R; Mayer, LD, 1997
)
0.3
"The metabolism of valspodar (PSC 833; PSC), which is developed as a multidrug resistance-reversing agent, was investigated to assess the potential for drug-drug interactions and the pharmacological activity of major metabolites."( The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite.
Cohen, D; Fischer, V; Hauck, C; Heitz, F; Rodríguez-Gascón, A; Tynes, R; Vickers, AE, 1998
)
0.3
" There was no clinically relevant change in the effect of digoxin on vital signs or electrocardiographic parameters when administered with single- or multiple-dose valspodar compared with administration alone in volunteers with healthy cardiovascular systems."( Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin.
Gerbeau, C; Guerret, M; Kovarik, JM; Rigaudy, L; Rost, KL, 1999
)
0.3
"It is necessary to decrease the doses of daunorubicin and etoposide when they are administered with PSC-833, presumably because of the effect of the modulator on the pharmacokinetics of these agents."( Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia g
Baer, M; Caligiuri, M; Dodge, RK; George, SL; Lee, EJ; Lemke, S; Powell, BL; Schiffer, CA; Smith, R; Szatrowski, TP, 1999
)
0.3
"To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetics of paclitaxel when given with PSC 833 (valspodar) to patients with refractory solid tumors."( Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.
Cazenave, LA; Egorin, MJ; Fears, CA; Fears, CL; Fracasso, PM; Litchman, M; Rosen, DM; Westerveldt, P; Westervelt, P; Zuhowski, EG, 2000
)
0.31
" We conducted a phase I study of a 7-day oral administration of PSC 833 in combination with paclitaxel, administered as a 96-hour continuous infusion."( Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.
Abraham, J; Bakke, S; Bates, S; Bergan, R; Chico, I; Choyke, P; Figg, WD; Fojo, T; Goldspiel, B; Kang, MH; Meadows, B; Merino, M; Robey, R; Rutt, A; Smith, T; Steinberg, S, 2001
)
0.31
"In combination with PSC 833, maximum-tolerated doses were defined as paclitaxel 13."( Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.
Abraham, J; Bakke, S; Bates, S; Bergan, R; Chico, I; Choyke, P; Figg, WD; Fojo, T; Goldspiel, B; Kang, MH; Meadows, B; Merino, M; Robey, R; Rutt, A; Smith, T; Steinberg, S, 2001
)
0.31
"PSC 833 in combination with paclitaxel can be administered safely to patients provided the paclitaxel dose is reduced to compensate for the pharmacokinetic interaction."( Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.
Abraham, J; Bakke, S; Bates, S; Bergan, R; Chico, I; Choyke, P; Figg, WD; Fojo, T; Goldspiel, B; Kang, MH; Meadows, B; Merino, M; Robey, R; Rutt, A; Smith, T; Steinberg, S, 2001
)
0.31
" We reexamined their cytotoxicity in defined cell lines both as single agents and in combination with agents which may be of value in human malignant disease."( A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents.
Budman, DR; Calabro, A; Kreis, W, 2001
)
0.31
" Synergistic or additive effects were demonstrated in all three prostate cell lines when PSC 833 was combined with estramustine, etoposide, ketoconazole, suramin, or vinorelbine in the prostate cancer cell lines."( A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents.
Budman, DR; Calabro, A; Kreis, W, 2001
)
0.31
"PSC 833 or cyclosporin alone or in combination with other agents may have an anticancer effect independently of their modulatory action on MDR."( A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents.
Budman, DR; Calabro, A; Kreis, W, 2001
)
0.31
"To determine the maximum-tolerated dose (MTD) of doxorubicin when given in combination with cisplatin and the multidrug-resistance (MDR) modulator valspodar and the remission rate induced by this combination in patients with platinum- and anthracycline-resistant ovarian cancer."( Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer.
Baekelandt, M; Gustavssson, B; Kristensen, GB; Lehne, G; Pfeiffer, P; Szántó, I; Tropé, CG, 2001
)
0.31
" The MTD of doxorubicin was determined to be 35 mg/m(2) when administered with valspodar at 2 mg/kg loading dose and 10 mg/kg/d CIVI plus 50 mg/m(2) cisplatin."( Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer.
Baekelandt, M; Gustavssson, B; Kristensen, GB; Lehne, G; Pfeiffer, P; Szántó, I; Tropé, CG, 2001
)
0.31
" The authors conducted a Phase I study of orally administered PSC 833 in combination with vinblastine administered as a 5-day continuous infusion."( A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
Bakke, S; Bates, S; Bergan, R; Chen, C; Chico, I; Choyke, P; Figg, WD; Fojo, T; Goldspiel, B; Kang, M; Meadows, B; Merino, M; Robey, R; Smith, T, 2001
)
0.31
"PSC 833 in combination with vinblastine can be administered safely to patients provided the vinblastine dose is adjusted for pharmacokinetic interactions."( A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
Bakke, S; Bates, S; Bergan, R; Chen, C; Chico, I; Choyke, P; Figg, WD; Fojo, T; Goldspiel, B; Kang, M; Meadows, B; Merino, M; Robey, R; Smith, T, 2001
)
0.31
" It is concluded that Valspodar 10 mg/kg per 24 h in combination with daunorubicin 45 mg/m(2) for 3 days and cytarabine 1 g/m(2) twice daily for 4 days is tolerable in this heavily pre-treated group of patients."( A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia.
Björkholm, M; Brinch, L; Evensen, S; Gruber, A; Gustavsson, B; Hedenus, M; Juliusson, G; Liliemark, J; Löfvenberg, E; Nesthus, I; Paul, C; Simonsson, B; Sjo, M; Stenke, L; Tangen, JM; Tidefelt, U; Udén, AM, 2003
)
0.32
"To study the intrinsic parameters of P-glycoprotein (P-gp) transport and drug-drug interactions at the blood-brain barrier (BBB), as few quantitative in vivo data are available."( In situ transport of vinblastine and selected P-glycoprotein substrates: implications for drug-drug interactions at the mouse blood-brain barrier.
Cisternino, S; Debray, M; Rousselle, C; Scherrmann, JM, 2004
)
0.32
" Drug-drug interactions were examined using vinblastine and compounds that bind to P-gp sites (verapamil, progesterone, PSC833) other than the vinblastine site to take into account the multispecific drug P-gp recognition."( In situ transport of vinblastine and selected P-glycoprotein substrates: implications for drug-drug interactions at the mouse blood-brain barrier.
Cisternino, S; Debray, M; Rousselle, C; Scherrmann, JM, 2004
)
0.32
" In situ perfusion of mdr1a(-/-) and wild-type mouse brains could be used to predict drug-drug interactions for P-gp at the mouse BBB."( In situ transport of vinblastine and selected P-glycoprotein substrates: implications for drug-drug interactions at the mouse blood-brain barrier.
Cisternino, S; Debray, M; Rousselle, C; Scherrmann, JM, 2004
)
0.32
" Because of interaction of valspodar with vincristine and doxorubicin, the doses of these drugs were reduced compared with the VAD-alone arm, and the doxorubicin was further reduced in the last 15 patients when given with valspodar based on pharmacokinetic and toxicity studies."( Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group.
Blood, EA; Dalton, WS; Friedenberg, WR; Greipp, PR; Larson, RA; Rue, M; Shustik, C; Sonneveld, P, 2006
)
0.33
" Each patient received one cycle of intravenous etoposide (100 mg/m2 daily for 3 days on three consecutive weeks) to document baseline pharmacokinetics, and subsequently the same schedule using a dose of 50 mg/m2 was given combined with PSC 833 given orally every 6h at a starting dose of 4 mg/kg."( Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours.
Berthaud, P; Dick, G; Pein, F; Pinkerton, R; Pritchard-Jones, K; Vassal, G, 2007
)
0.34
"To compare the safety and efficacy of carboplatin and paclitaxel administered with or without the multidrug resistance modulator valspodar (PSC 833) in untreated patients with advanced ovarian or primary peritoneal cancer."( Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer.
Baekelandt, MM; Dugan, MH; Fracasso, PM; Gordon, AN; Joly, F; Jones, GJ; Lhommé, C; Lissoni, AA; Manikhas, GM; Mietlowski, WL; Nicoletto, MO; Walker, JL, 2008
)
0.35
"In vitro assessment of drug candidates' affinity for multi-drug resistance proteins is of crucial importance for the prediction of in vivo pharmacokinetics and drug-drug interactions."( Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions.
Gnoth, MJ; Grieshop, B; Ickenroth, K; Muenster, U, 2008
)
0.35
" In order to not overlook potential drug-drug interactions when testing drug candidates for inhibitory potential towards Bcrp, distinct Bcrp probe substrates should be used."( Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions.
Gnoth, MJ; Grieshop, B; Ickenroth, K; Muenster, U, 2008
)
0.35
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
" Drug-drug interactions (DDIs) based on P-gp/CYP3A interplay are of clinical importance and require preclinical investigation."( The Consequence of Drug-Drug Interactions Influencing the Interplay between P-Glycoprotein and Cytochrome P450 3a: An Ex Vivo Study with Rat Precision-Cut Intestinal Slices.
de Graaf, IA; de Jager, MH; Groothuis, GM; Li, M; Siissalo, S; van Dam, A, 2016
)
0.43
"Intestinal P-gp and CYP3A4 work coordinately to reduce the intracellular concentration of drugs, and drug-drug interactions (DDIs) based on this interplay are of clinical importance and require pre-clinical investigation."( The consequence of regional gradients of P-gp and CYP3A4 for drug-drug interactions by P-gp inhibitors and the P-gp/CYP3A4 interplay in the human intestine ex vivo.
de Graaf, IA; de Jager, MH; Groothuis, GM; Li, M; van de Steeg, E, 2017
)
0.46
"A novel surface plasmon resonance-based P-gp ligand screening system (SPR-PLSS) combined with lentiviral particle (LVP) stabilization strategy was constructed to screen out potential P-gp inhibitors from natural products."( Surface plasmon resonance biosensor combined with lentiviral particle stabilization strategy for rapid and specific screening of P-Glycoprotein ligands.
Cai, Y; Cao, Y; Chai, Y; Chen, L; Chen, X; Hong, Z; Liu, Y; Shi, Y; Wang, D; Zhu, Z, 2021
)
0.62
"5 mg/m 2 ) of 175 mg/m 2 (full dose) was administered with valspodar 5 mg/kg orally 4 times daily for 12 doses."( A Phase I Trial of the ABCB1 Inhibitor, Oral Valspodar, in Combination With Paclitaxel in Patients With Advanced Solid Tumors.
Beumer, JH; Egorin, MJ; Fears, CL; Fisher, GA; Fracasso, PM; Goodner, SA; Jones, GJ; Pearce, TE; Sikic, BI; Wildi, JD, 2023
)
0.91

Bioavailability

The study found a 10-fold increased oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. However, no survival increase could be achieved with the AC alone.

ExcerptReferenceRelevance
" Bioavailability and blood levels of VP 16-213 were significantly increased 30 min after administration if PSC 833 had been given before."( Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity.
Altermatt, HJ; Donatsch, P; Hiestand, PC; Keller, RP; Laissue, JA; Zihlmann, H, 1992
)
0.52
" As part of early clinical development of PSC 833, the authors investigated the bioavailability of an oral formulation of PSC 833."( Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist.
Bates, S; Figg, WD; Fojo, AT; Kalafsky, G; Lush, RM; Meadows, B; Smith, HT, 1997
)
0.3
" We show here a 10-fold increased oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833."( Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
Beijnen, JH; Borst, P; Nooijen, WJ; Schinkel, AH; Sparreboom, A; van Asperen, J; van Tellingen, O, 1997
)
0.73
" These data demonstrate that P-glycoprotein limits the oral bioavailability and penetration of these agents into the brain."( The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.
Fromm, MF; Kim, RB; Leake, B; Roden, DM; Wandel, C; Wilkinson, GR; Wood, AJ, 1998
)
0.3
" However, an increased AC bioavailability is not sufficient to explain the therapeutic benefit of SDZ PSC 833 co-treatment in MDR tumour-bearing mice: in these animals, no survival increase could be achieved with the AC alone by simply increasing the cytotoxin dosage up to doses that were severely toxic for the non-tumour-bearing mice."( [SDZ PSC 833: a novel modulator of MDR].
Covelli, A,
)
1.26
" The microemulsion dosage forms were bioequivalent with absolute bioavailability nearly double that of the conventional oral solution."( Optimizing the absorption of valspodar, a P-glycoprotein modulator, Part I: Selecting an oral formulation and exploring its clinical pharmacokinetics/dynamics.
Hensel, S; Holt, B; Kovarik, JM; Lücker, PW; Mueller, EA; Preisig-Flückiger, SS; Uresin, Y, 1997
)
0.3
" Absolute bioavailability from the microemulsion formulation was 60%."( Optimizing the absorption of valspodar, a P-glycoprotein modulator, Part II: Quantifying its pharmacokinetic variability and refining the bioavailability estimate.
Kovarik, JM; Mueller, EA; Richard, F; Tetzloff, W, 1997
)
0.3
" Coadministration of MDR1-related chemotherapeutic drugs with an MDR modulator may enhance the bioavailability of these agents sufficiently to enable oral dosing, which would potentially be more convenient and less toxic."( Modulation of multidrug resistance: a paradigm for translational clinical research.
Sikic, BI, 1999
)
0.3
" In addition, its role in modifying the bioavailability of orally administered drugs via induction or inhibition has been also been demonstrated in various studies."( Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs.
Krishna, R; Mayer, LD, 2000
)
0.31
" To avoid the confounding drug transport provided by P-glycoprotein (P-gp), the roles of Bcrp1 in the bioavailability of topotecan and the effect of GF120918 were studied in both wild-type and P-gp-deficient mice and their fetuses."( Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
Beijnen, JH; Brinkhuis, RF; Jonker, JW; Maliepaard, M; Schellens, JH; Schinkel, AH; Smit, JW, 2000
)
0.31
" When both topotecan and GF120918 were administered orally, the bioavailability (i."( Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
Beijnen, JH; Brinkhuis, RF; Jonker, JW; Maliepaard, M; Schellens, JH; Schinkel, AH; Smit, JW, 2000
)
0.31
" A new formulation of the drug has recently been developed with better oral bioavailability (60%) and less interindividual variability."( Technology evaluation: Valspodar, Novartis AG.
Tai, HL, 2000
)
0.31
" For the taxanes paclitaxel and docetaxel, however, low oral bioavailability has limited development of treatment by the oral route."( Oral delivery of taxanes.
Beijnen, JH; Malingré, MM; Schellens, JH, 2001
)
0.31
"It has been suggested that cytochrome P450 3A4 (CYP3A4) and MDR1 P-glycoprotein (P-gp) act synergistically to limit the bioavailability of orally administered agents."( Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4.
Achira, M; Ito, K; Sugiyama, Y; Suzuki, H, 1999
)
0.3
" Increased oral bioavailability and increased peak and trough concentrations were observed with the microemulsion formulation."( A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
Bakke, S; Bates, S; Bergan, R; Chen, C; Chico, I; Choyke, P; Figg, WD; Fojo, T; Goldspiel, B; Kang, M; Meadows, B; Merino, M; Robey, R; Smith, T, 2001
)
0.31
" In this study, we demonstrated that coadministration of the MDR-reversing agent MS-209, which is known to inhibit P-glycoprotein function by direct interaction, improved the bioavailability of orally administered paclitaxel and consequently enhanced its antitumor activity."( P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
Aoki, J; Kimura, Y; Kohno, M; Nakanishi, O; Ooka, H; Tsuruo, T, 2002
)
0.31
"The present study suggests that coadministration of MS-209 may be a useful way to improve the bioavailability of drugs not suitable for oral administration due to elimination via the intestinal tract."( P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
Aoki, J; Kimura, Y; Kohno, M; Nakanishi, O; Ooka, H; Tsuruo, T, 2002
)
0.31
"P-glycoprotein inhibitors can increase the oral bioavailability of paclitaxel."( Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice.
Bardelmeijer, HA; Beijnen, JH; Ouwehand, M; Schellens, JH; van Tellingen, O, 2004
)
0.32
"To investigate whether P-glycoprotein (P-gp) and multidrug resistance proteins (MRPs), which limit the bioavailability of HIV protease inhibitors (PIs) and nucleoside reverse transcriptase inhibitors (NRTIs), modulate the anti-HIV activity of NRTIs, non-NRTIs and PIs in vitro."( ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages.
Becher, F; Benech, H; Clayette, P; Dereuddre-Bosquet, N; Dormont, D; Garrigues, A; Grassi, J; Jorajuria, S; Mabondzo, A; Martin, S; Orlowski, S; Porcheray, F, 2004
)
0.32
" Because efflux pumps, as P-glycoprotein (P-gp), serve both as natural defense mechanisms and influence the bioavailability and disposition of drugs, we analyzed the ability of diazinon to act as efflux modulator."( Effect of organophosphate pesticide diazinon on expression and activity of intestinal P-glycoprotein.
Lecoeur, S; Mazallon, M; Videmann, B, 2006
)
0.33
"Valspodar increased methadone's bioavailability as consequence of P-gp inhibition, which resulted in an increased analgesic effect of methadone."( Modeling methadone pharmacokinetics in rats in presence of P-glycoprotein inhibitor valspodar.
Calvo, R; Ortega, I; Perez-Ruixo, JJ; Rodriguez, M; Suarez, E, 2007
)
0.34
" The mean bioavailability of valspodar was 42."( Pharmacokinetics of PSC 833 (valspodar) in its Cremophor EL formulation in rat.
Binkhathlan, Z; Brocks, DR; Hamdy, DA; Lavasanifar, A, 2010
)
0.36

Dosage Studied

The increased AC bioavailability is not sufficient to explain the therapeutic benefit of SDZ PSC 833 co-treatment in MDR tumour-bearing mice. In these animals, no survival increase could be achieved with the AC alone.

ExcerptRelevanceReference
" The dose-response curves were nearly identical and did not demonstrate differences in modulator potency."( Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor.
Friche, E; Jensen, PB; Nissen, NI, 1992
)
0.28
"-injected anticancer drugs in optimal schedule and dosage induced apparent cures in some leukemic mice, whereas no cures were obtained with the cyclosporin A/anticancer drug combinations."( Modulation of multidrug resistance by SDZ PSC 833 in leukemic and solid-tumor-bearing mouse models.
Cohen, D; Itoh, Y; Naito, M; Oh-hara, T; Tsuruo, T; Watanabe, T, 1996
)
0.57
" dosage form of PSC 833, [3'-keto-Bmt1]-[Val2]-cyclosporin, contains CreEL and has been presumed to have the potentiation of the reversal activity of PSC 833."( Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models.
Itoh, Y; Naito, M; Nakayama, Y; Oh-hara, T; Tsuruo, T; Watanabe, T, 1996
)
0.29
"4 mg/L during the dosing period, comparable with concentrations of PSC that modulate Pgp in vitro."( HPLC method for monitoring SDZ PSC 833 in whole blood.
Crimmins, DL; Fracasso, PM; Hock, KG; Scott, MG, 1997
)
0.59
" infusion during 2 hours) or colchicine alone (the same dosage with SDZ PSC 833 vehicle)."( Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine.
Desrayaud, S; Guntz, P; Lemaire, M; Scherrmann, JM, 1997
)
0.8
" PSC 833 in single and multiple dosage regimens over a 15-day study period."( Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
Krishna, R; Mayer, LD, 1997
)
0.3
" However, an increased AC bioavailability is not sufficient to explain the therapeutic benefit of SDZ PSC 833 co-treatment in MDR tumour-bearing mice: in these animals, no survival increase could be achieved with the AC alone by simply increasing the cytotoxin dosage up to doses that were severely toxic for the non-tumour-bearing mice."( [SDZ PSC 833: a novel modulator of MDR].
Covelli, A,
)
1.26
" The two microemulsion dosage forms demonstrated significantly faster and less variable rates of absorption compared with the conventional oral solution."( Optimizing the absorption of valspodar, a P-glycoprotein modulator, Part I: Selecting an oral formulation and exploring its clinical pharmacokinetics/dynamics.
Hensel, S; Holt, B; Kovarik, JM; Lücker, PW; Mueller, EA; Preisig-Flückiger, SS; Uresin, Y, 1997
)
0.3
" A dose-response relationship was shown between the concentration of PSC 833 in the blood and the inhibition of rhodamine efflux, with an apparent plateau of the inhibition of rhodamine efflux at approximately 1,000 ng/mL."( Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833.
Bakke, S; Bates, S; Fojo, T; Litman, T; Meadows, B; Patil, S; Robey, R; Smith, T; Stein, W, 1999
)
0.3
" This fact permits the use of high Drol Z dosage in order to achieve a relevant modulating effect in vivo and to use this drug in combination with a further modulator so as to reach maximum efficacy with tolerable side effects."( In vitro efficacy of known P-glycoprotein modulators compared to droloxifene E and Z: studies on a human T-cell leukemia cell line and their resistant variants.
Gieseler, F; Gullis, E; Hasmann, M; Löser, R; Nüssler, V; Pelka-Fleisc, R; Stötzer, O; Wilmanns, W; Zwierzina, H, 1998
)
0.3
" Daunorubicin dose-response curves were generated by non-linear regression of electronically measured cell counts of 72- - 96-h cultures."( Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP).
den Boer, M; Lehne, G; Mørkrid, L; Rugstad, HE, 2000
)
0.31
" These data suggest that the addition of PSC 833 to an M/E regimen for older patients with untreated AML is well tolerated but requires a reduction in M/E dosing to avoid increased toxicity."( A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617.
Anderson, JE; Appelbaum, FR; Chauncey, TR; Chen, I; Godwin, JE; Head, DR; Kalaycio, ME; Kopecky, KJ; Kraut, EH; Leith, CP; Luthardt, FW; Moore, DF; Petersdorf, SH; Rankin, C; Shurafa, MS; Willman, CL, 2000
)
0.31
" Dose-response curves were generated for two modulators of Pgp function, GG918 and PSC833."( In vitro comparison of sestamibi, tetrofosmin, and furifosmin as agents for functional imaging of multidrug resistance in tumors.
Ballinger, JR; Moore, MJ; Muzzammil, T, 2000
)
0.31
" This in turn will facilitate dosing to achieve comparable CPss and AUCs."( Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.
Abraham, J; Bakke, S; Bates, S; Bergan, R; Chico, I; Choyke, P; Figg, WD; Fojo, T; Goldspiel, B; Kang, MH; Meadows, B; Merino, M; Robey, R; Rutt, A; Smith, T; Steinberg, S, 2001
)
0.31
" Liposomal preparations of PSC833 may provide a useful alternative dosage form for intravenous administration of PSC 833 to be combined with anticancer drugs to circumvent drug resistance in cancer chemotherapy."( Effect of PSC 833 liposomes and Intralipid on the transport of epirubicin in Caco-2 cells and rat intestines.
Cherng, J; Liu, F; Lo, Y, 2001
)
0.31
" To study the effects of PSC on liver cancer development, a daily dose of 30 mg PSC/kg body wt (PSC30) was chosen based on an initial dose-response experiment."( Effect of PSC 833, an inhibitor of P-glycoprotein, on 1,2-dimethylhydrazine-induced liver carcinogenesis in rats.
Bradley, G; Kankesan, J; Laconi, E; Ling, V; Rajalakshmi, S; Rao, PM; Sarma, DS; Thiessen, JJ; Vanama, R; Yusuf, A, 2003
)
0.32
" Dosing at ZT15 rather than ZT3 reduced mean leucopenia (9% vs 53%; p<0."( Optimization of irinotecan chronotherapy with P-glycoprotein inhibition.
Berland, E; Filipski, E; Guettier, C; Lévi, F; Okyar, A; Ozturk, N; van der Horst, GT, 2014
)
0.4
" Here we attempted to perform the combinatorial drug therapy with P-glycoprotein (P-gp) inhibitors to lower therapeutic dosage of PGB in the intermittent cold stress-induced fibromyalgia-like pain model."( P-glycoprotein inhibitors improve effective dose and time of pregabalin to inhibit intermittent cold stress-induced central pain.
Fujita, W; Mukae, T; Ueda, H, 2016
)
0.43
" The chemical inhibitor was dosed intravenously via the femoral artery, and a cassette of known substrates was infused via the jugular vein."( Optimization of dose and route of administration of the P-glycoprotein inhibitor, valspodar (PSC-833) and the P-glycoprotein and breast cancer resistance protein dual-inhibitor, elacridar (GF120918) as dual infusion in rats.
Grater, R; Kapadnis, S; Pietrasiewicz, A; Qiu, D; Rowbottom, C; Trapa, P; Tuczewycz, T, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
homodetic cyclic peptideA homodetic cyclic peptide is a cyclic peptide in which the ring consists solely of amino-acid residues in peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-dependent translocase ABCB1Homo sapiens (human)IC50 (µMol)0.39690.00022.318510.0000AID672543; AID679902; AID680136; AID680504; AID681358
ATP-dependent translocase ABCB1Homo sapiens (human)Ki0.71700.02002.35948.5900AID680075; AID680092
Multidrug resistance-associated protein 1 Homo sapiens (human)Ki27.00000.07002.20208.1000AID679985
Canalicular multispecific organic anion transporter 1Homo sapiens (human)Ki28.90004.70006.40508.1100AID678981
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-dependent translocase ABCB1Homo sapiens (human)EC50 (µMol)0.26000.01600.67863.1000AID678838; AID679466
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (36)

Processvia Protein(s)Taxonomy
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
leukotriene metabolic processMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 1 Homo sapiens (human)
response to xenobiotic stimulusMultidrug resistance-associated protein 1 Homo sapiens (human)
cobalamin transportMultidrug resistance-associated protein 1 Homo sapiens (human)
sphingolipid biosynthetic processMultidrug resistance-associated protein 1 Homo sapiens (human)
cellular response to oxidative stressMultidrug resistance-associated protein 1 Homo sapiens (human)
heme catabolic processMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic transportMultidrug resistance-associated protein 1 Homo sapiens (human)
phospholipid translocationMultidrug resistance-associated protein 1 Homo sapiens (human)
positive regulation of inflammatory responseMultidrug resistance-associated protein 1 Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
cell chemotaxisMultidrug resistance-associated protein 1 Homo sapiens (human)
transepithelial transportMultidrug resistance-associated protein 1 Homo sapiens (human)
cyclic nucleotide transportMultidrug resistance-associated protein 1 Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 1 Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
sphingolipid translocationMultidrug resistance-associated protein 1 Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 1 Homo sapiens (human)
cellular response to amyloid-betaMultidrug resistance-associated protein 1 Homo sapiens (human)
carboxylic acid transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierMultidrug resistance-associated protein 1 Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type vitamin B12 transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATPase-coupled lipid transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
sphingolipid transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
carboxylic acid transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
basal plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
lateral plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
extracellular exosomeMultidrug resistance-associated protein 1 Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (55)

Assay IDTitleYearJournalArticle
AID679896TP_TRANSPORTER: inhibition of cyclosporin A transcellular transport by PSC833 at a concentration of 30uM in MDR1-expressing MDCKII cells2007Neuropharmacology, Feb, Volume: 52, Issue:2
Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.
AID1769284Inhibition of BCRP (unknown origin) expressed in HEK293/R2 cells assessed as conformational change by measuring increase in 5D3 shift at 1 uM preincubated for 15 mins followed by FITC mouse antihuman BCRP antibody addition measured after 30 mins by flow c2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Flavonoid Monomers as Potent, Nontoxic, and Selective Modulators of the Breast Cancer Resistance Protein (ABCG2).
AID1213375Inhibition of BCRP-mediated [3H]estrone-3-sulfate transport in human Caco2 cells at 1 uM after 30 mins2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates.
AID678732TP_TRANSPORTER: inhibition of phenytoin transcellular transport by PSC833 at a concentration of 30uM in mdr1a-expressing LLC-PK1 cells2007Neuropharmacology, Feb, Volume: 52, Issue:2
Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.
AID679027TP_TRANSPORTER: inhibition of Fluo-3 secretion into apical vacuoles (Fluo-3: 1 uM, PSC 833: 50 uM) in WIF-B cells1998Hepatology (Baltimore, Md.), Nov, Volume: 28, Issue:5
Expression of the apical conjugate export pump, Mrp2, in the polarized hepatoma cell line, WIF-B.
AID680422TP_TRANSPORTER: inhibition of MTX uptake (MTX: 1 uM, PSC-833: 10 uM) in membrane vesicles from MRP3-expressing HEK293 cells2001Cancer research, Oct-01, Volume: 61, Issue:19
Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID678735TP_TRANSPORTER: inhibition of cyclosporin A transcellular transport by PSC833 at a concentration of 30uM in mdr1a-expressing LLC-PK1 cells2007Neuropharmacology, Feb, Volume: 52, Issue:2
Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.
AID680810TP_TRANSPORTER: increase in Vincristine intracellular accumulation (Vincristine: 1 uM, PSC-833: 10 uM) in MRP2-expressing LLC PK1 cells1999Molecular pharmacology, Dec, Volume: 56, Issue:6
Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter.
AID681912TP_TRANSPORTER: inhibition of MTX uptake (MTX: 20 uM, PSC-833: 10 uM) in membrane vesicles from MRP4-expressing Sf9 cells2002Cancer research, Jun-01, Volume: 62, Issue:11
Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system.
AID714200Inhibition of P-gp-mediated paclitaxel resistance in human LCC6MDR cells assessed as fold decrease in paclitaxel IC50 for cytotoxic activity at 1 uM after 5 days by MTS assay relative to parental cells2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Amine linked flavonoid dimers as modulators for P-glycoprotein-based multidrug resistance: structure-activity relationship and mechanism of modulation.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID678838TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.25 uM) in MDR-CEM cells1996Anti-cancer drugs, Jul, Volume: 7, Issue:5
Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay.
AID678908TP_TRANSPORTER: increase in Quinidine concentration in brain in FVB mouse1997The Journal of pharmacology and experimental therapeutics, Nov, Volume: 283, Issue:2
P-Glycoprotein mediates the efflux of quinidine across the blood-brain barrier.
AID1213372Inhibition of P-gp-mediated [3H]-digoxin transport in human Caco2 cells at 1 uM after 30 mins2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates.
AID672543Inhibition of P-glycoprotein-mediated daunorubicin efflux from human CCRF-CEM/VCR1000 cells after 240 secs by FACS flow cytometric analysis2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Structure-activity relationships, ligand efficiency, and lipophilic efficiency profiles of benzophenone-type inhibitors of the multidrug transporter P-glycoprotein.
AID1163797Reversal of P-gp-mediated resistance to doxorubicin in human SW620/AD300 cells assessed as reduction in doxorubin IC50 at 400 nM after 72 hrs by SRB assay2014Journal of natural products, Sep-26, Volume: 77, Issue:9
Polyoxypregnane steroids from the stems of Marsdenia tenacissima.
AID680121TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing LLC-PK1 cells1998Japanese journal of cancer research : Gann, Nov, Volume: 89, Issue:11
Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein.
AID681358TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells2000Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 28, Issue:6
Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID680492TP_TRANSPORTER: inhibition of Indinavir transepithelial transport (basal to apical) (Indinavir: 5 uM, PSC-833: 1 uM) in Caco-2 cells1998The Journal of clinical investigation, Jan-15, Volume: 101, Issue:2
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.
AID680075TP_TRANSPORTER: inhibition of Calcein-AM efflux in CEM/VBL 100 cells1999Biochemical and biophysical research communications, Apr-13, Volume: 257, Issue:2
PSC833, cyclosporin A, and dexniguldipine effects on cellular calcein retention and inhibition of the multidrug resistance pump in human leukemic lymphoblasts.
AID482109Inhibition of P-gp-mediated paclitaxel-resistance in P-glycoprotein-expressing human LCC-6 cells assessed as fold decrease in paclitaxel IC50 for cytotoxic activity at 1 uM after 5 days by MTS assay relative to control2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Design and syntheses of permethyl ningalin B analogues: potent multidrug resistance (MDR) reversal agents of cancer cells.
AID680504TP_TRANSPORTER: inhibition of Doxorubicin transepithelial transport (basal to apical) (Doxorubicin: 0.8 uM) in MDR1-expressing LLC-PK1 cells1998Japanese journal of cancer research : Gann, Nov, Volume: 89, Issue:11
Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein.
AID678777TP_TRANSPORTER: increase in brain concentration in mdr1a(-/-) mouse1998The Journal of pharmacology and experimental therapeutics, May, Volume: 285, Issue:2
Effect of the Mdr1a P-glycoprotein gene disruption on the tissue distribution of SDZ PSC 833, a multidrug resistance-reversing agent, in mice.
AID680011TP_TRANSPORTER: inhibition of Fexofenadine uptake (Fexofenadine: 2 uM, PSC-833: 100 uM) in Xenopus laevis oocytes1999Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 27, Issue:8
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
AID679923TP_TRANSPORTER: inhibition of Saquinavir transepithelial transport (basal to apical) (Saquinavir: 5 uM, PSC-833: 1 uM) in Caco-2 cells1998The Journal of clinical investigation, Jan-15, Volume: 101, Issue:2
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID680475TP_TRANSPORTER: inhibition of Nelfinavir transepithelial transport (basal to apical) (Nrlfinavir: 5 uM, PSC-833: 1 uM) in Caco-2 cells1998The Journal of clinical investigation, Jan-15, Volume: 101, Issue:2
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.
AID678981TP_TRANSPORTER: inhibition of LTC4 uptake in membrane vesicles from MRP2-expressing LLC PK1 cells1999Molecular pharmacology, Dec, Volume: 56, Issue:6
Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter.
AID679026TP_TRANSPORTER: inhibition of Fluo-3 uptake (Fluo-3: 4.4 uM, PSC 833: 10 uM) in bile canalicular membrane vesicles from Wistar rat1998Hepatology (Baltimore, Md.), Nov, Volume: 28, Issue:5
Expression of the apical conjugate export pump, Mrp2, in the polarized hepatoma cell line, WIF-B.
AID714413Inhibition of P-gp-mediated paclitaxel resistance in human LCC6MDR cells assessed as fold decrease in paclitaxel IC50 for cytotoxic activity at 0.5 uM after 5 days by MTS assay relative to parental cells2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Amine linked flavonoid dimers as modulators for P-glycoprotein-based multidrug resistance: structure-activity relationship and mechanism of modulation.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID680287TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 uM, PSC-833: 8 uM) in MDR1-expressing NIH-3T3 cells2004Biochemical and biophysical research communications, Mar-19, Volume: 315, Issue:4
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
AID680136TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 uM) in MDR1-expressing LLC-PK1 cells2000Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 28, Issue:10
Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID680092TP_TRANSPORTER: inhibition of ATPase activity (Verapamil) in P-gp-MRP-16-Protein A complex1997British journal of pharmacology, Sep, Volume: 122, Issue:2
Interaction of cyclosporin derivatives with the ATPase activity of human P-glycoprotein.
AID678733TP_TRANSPORTER: inhibition of levetiracetam transcellular transport by PSC833 at a concentration of 30uM in mdr1a-expressing LLC-PK1 cells2007Neuropharmacology, Feb, Volume: 52, Issue:2
Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.
AID679902TP_TRANSPORTER: inhibition of Vinblastine transepithelial transport (basal to apical) (Vinblastine: 0.1 uM) in MDR1-expressing LLC-PK1 cells1998Japanese journal of cancer research : Gann, Nov, Volume: 89, Issue:11
Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1163806Reversal of P-gp-mediated resistance assessed as ratio of doxorubicin IC50 for human SW620/AD300 cells to doxorubicin IC50 for human SW620 cells in presence of compound at 400 nM2014Journal of natural products, Sep-26, Volume: 77, Issue:9
Polyoxypregnane steroids from the stems of Marsdenia tenacissima.
AID679985TP_TRANSPORTER: inhibition of LTC4 uptake in membrane vesicle from MRP1-expressing HeLa cells1994The Journal of biological chemistry, Nov-11, Volume: 269, Issue:45
The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates.
AID714416Cytotoxicity against mouse L929 cells after 72 hrs2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Amine linked flavonoid dimers as modulators for P-glycoprotein-based multidrug resistance: structure-activity relationship and mechanism of modulation.
AID680494TP_TRANSPORTER: inhibition of IAAP photoaffinity labelling (IAAP: 0.02 uM, PSC-833: 100-fold molar excess) in plasma membranes from CEM/VLB1.0 cells1997Biochemical pharmacology, Jan-10, Volume: 53, Issue:1
Reversal of P-glycoprotein-associated multidrug resistance by ivermectin.
AID680318TP_TRANSPORTER: efflux of 3uM mitoxantrone in the presence of PSC-833 (Valspodar) at a concentration of 2.5uM in MCF7/R cells2004Cancer chemotherapy and pharmacology, May, Volume: 53, Issue:5
Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023.
AID1163794Reversal of P-gp-mediated resistance to doxorubicin in human SW620 cells assessed as reduction in doxorubin IC50 at 400 nM after 72 hrs by SRB assay2014Journal of natural products, Sep-26, Volume: 77, Issue:9
Polyoxypregnane steroids from the stems of Marsdenia tenacissima.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID714414Cytotoxicity against human MDA435/LCC6MDR cells expressing MDR after 72 hrs2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Amine linked flavonoid dimers as modulators for P-glycoprotein-based multidrug resistance: structure-activity relationship and mechanism of modulation.
AID714415Cytotoxicity against human LCC-6 cells after 72 hrs2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Amine linked flavonoid dimers as modulators for P-glycoprotein-based multidrug resistance: structure-activity relationship and mechanism of modulation.
AID679466TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.25 uM) in MDR-P388 cells1996Anti-cancer drugs, Jul, Volume: 7, Issue:5
Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay.
AID681278TP_TRANSPORTER: inhibition of Topotecan transepithelial transport (basal to apical) in Bcrp1-expressing LLC-PK1 cells2000Journal of the National Cancer Institute, Oct-18, Volume: 92, Issue:20
Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (430)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's153 (35.58)18.2507
2000's198 (46.05)29.6817
2010's66 (15.35)24.3611
2020's13 (3.02)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials55 (12.09%)5.53%
Reviews24 (5.27%)6.00%
Case Studies1 (0.22%)4.05%
Observational0 (0.00%)0.25%
Other375 (82.42%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]